- Home
- NPWR vs PHAR Comparison
NPWR vs PHAR Comparison
Compare NPWR & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPWR
- PHAR
- Stock Information
- Founded
- NPWR 2010
- PHAR 1988
- Country
- NPWR United States
- PHAR Netherlands
- Employees
- NPWR N/A
- PHAR N/A
- Industry
- NPWR Industrial Machinery/Components
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NPWR Energy
- PHAR Health Care
- Exchange
- NPWR Nasdaq
- PHAR Nasdaq
- Market Cap
- NPWR 726.1M
- PHAR 618.3M
- IPO Year
- NPWR N/A
- PHAR N/A
- Fundamental
- Price
- NPWR $8.43
- PHAR $8.20
- Analyst Decision
- NPWR Hold
- PHAR Strong Buy
- Analyst Count
- NPWR 2
- PHAR 3
- Target Price
- NPWR $9.50
- PHAR $27.00
- AVG Volume (30 Days)
- NPWR 580.5K
- PHAR 5.6K
- Earning Date
- NPWR 03-10-2025
- PHAR 03-13-2025
- Dividend Yield
- NPWR N/A
- PHAR N/A
- EPS Growth
- NPWR N/A
- PHAR N/A
- EPS
- NPWR 0.11
- PHAR N/A
- Revenue
- NPWR $250,000.00
- PHAR $285,745,000.00
- Revenue This Year
- NPWR N/A
- PHAR $20.08
- Revenue Next Year
- NPWR $6,300.00
- PHAR $9.22
- P/E Ratio
- NPWR $81.29
- PHAR N/A
- Revenue Growth
- NPWR 38.12
- PHAR 30.64
- 52 Week Low
- NPWR $6.57
- PHAR $6.65
- 52 Week High
- NPWR $14.28
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- NPWR 38.49
- PHAR 36.29
- Support Level
- NPWR $7.53
- PHAR $8.49
- Resistance Level
- NPWR $8.98
- PHAR $9.35
- Average True Range (ATR)
- NPWR 0.59
- PHAR 0.55
- MACD
- NPWR -0.08
- PHAR -0.17
- Stochastic Oscillator
- NPWR 34.32
- PHAR 12.14
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system which it refers to as the "NET Power Cycle is designed to produce clean, reliable and low-cost electricity from natural gas while capturing virtually all atmospheric emissions.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.